Financial Survey: Curis (NASDAQ:CRIS) and JATT Acquisition (NYSE:JATT)

JATT Acquisition (NYSE:JATT) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Earnings and Valuation

This table compares JATT Acquisition and Curis’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85 million	N/A	N/A
Curis	$10.02 million	6.55	-$47.41 million	($8.61)	-1.29

JATT Acquisition has higher earnings, but lower revenue than Curis.

Analyst Recommendations

This is a breakdown of current recommendations for JATT Acquisition and Curis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0	0	0	0	N/A
Curis	0	0	3	0	3.00

Curis has a consensus price target of $37.33, indicating a potential upside of 235.13%. Given Curis’ higher possible upside, analysts clearly believe Curis is more favorable than JATT Acquisition.

Institutional and Insider Ownership

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 5.7% of Curis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares JATT Acquisition and Curis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Curis	-486.45%	-224.75%	-60.88%

Summary

JATT Acquisition beats Curis on 6 of the 9 factors compared between the two stocks.

About JATT Acquisition

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

About Curis

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.